Chapter 96 Leader
The first person to speak was Chen Wen, director of the Department of Infectious Diseases.
He is the initiator of this multi-department seminar and the host of this seminar.
As soon as he finished speaking, a leading doctor from the Department of Hepatobiliary Surgery raised his hand and said:
“First of all, we must make it clear that hepatitis B and cirrhosis are two different diseases.”
"Long-term chronic hepatitis B can lead to cirrhosis, but cirrhosis is not only caused by hepatitis B; severe fatty liver and alcoholic liver disease can cause long-term inflammation of liver cells and eventually induce cirrhosis."
"Cirrhosis is a pathology Structural changes are irreversible."
"So, my suggestion is 'decompensation. There is no need to try it for patients with liver cirrhosis in the 'decompensation stage', which is equivalent to the liver function reducing to less than 50%. Toxicity will damage the liver again, which will most likely shorten the patient’s survival time, and the gains outweigh the losses.”
The doctors present nodded.
Moreover, this key doctor did not explain anything clearly.
Patients with decompensated liver cirrhosis are almost in the final stage, and "Ecofovir" has serious side effects. If someone dies while taking the drug, neither the hospital nor the doctor can bear the responsibility.
“I agree with Dr. Zhang that if we try to use ekofovir in patients with liver cirrhosis, it should only be used in the compensatory period.”
“However, Compared with the normal liver, the function of the liver in the compensation period is only about 70%. To put it harshly, it is just one step away from the decompensation period. Will the hepatotoxicity of 'Acofovir' directly cause the patient to enter the 'decompensation period'? ”
“Of course, I think that complete cure of hepatitis B will still be beneficial to patients with cirrhosis. It is possible to control the condition of patients with liver cirrhosis from worsening and allow patients to survive for a long time..."
"In general, I think this risk can be taken and can be tried."
The seminar quietly unfolded, and the doctors in the department each expressed their own opinions. After a heated discussion, "Ai "Kefuvir" is a treatment plan used in patients with compensated cirrhosis and is recognized by the vast majority of people.
Gradually, the content of the discussion became how to reduce the side effects of drugs and reduce liver damage in patients.
"My suggestion is to try combination therapy."
"First take 'tenofovir alafenamide' to reduce the amount of hepatitis B virus in the patient's body, and then take 'acprofenprofen' Wei', combined with injection of hepatoprotective drugs, to minimize the damage to the liver caused by 'Ecofovir'."
"However, we still need to try it in clinical practice as to which hepatoprotective drugs are effective, what dosage should be used, and whether combined use with 'icofenprofovir' will cause adverse reactions."
The doctors present nodded slightly.
"Icofenprofovir" is a new drug, and there is no clinical precedent for its combined use. Everything must be done with caution.
And this is also the greatest thing about clinical science, or in other words, the greatest thing about clinicians.
Pharmaceutical companies have almost completed their mission after producing the drug, but clinicians need to consider how to make better use of the drug and formulate various combination treatment plans to provide better treatment for patients.
The seminar was coming to an end, and two combined treatment plans were initially determined. Just as Chen Wen was about to end the meeting, Dr. Zhang, who spoke at the beginning, suddenly raised his hand and said:
"Director Chen, I have another suggestion. ”
“The key point now is to reduce the damage to the liver caused by the side effects of 'Ecofovir'. In this case , I think we can contact Qingshan Pharmaceutical to see if we can invite them in. "
"After all, they developed 'Acofovir', and the pharmaceutical toxicity and rejection are clearer than us, so yes. Let them guide us in using the medicine."
After the words fell, everyone's eyes lit up, and even Chen Wen nodded slightly.
Although pharmaceutical companies generally do not participate in the clinical treatment of drugs, everyone knows that the CEO of Qingshan Pharmaceutical, Zhang Yang, has a good relationship with Dean Zhou...
After thinking for a moment, Chen Wen agreed. : "I will report this matter to Dean Zhou. If we can invite Qing The participation of the yam industry will undoubtedly make us more confident in using medicine."
"Well, thank you for your hard work, today's seminar is over."
< br>Chen Wen acted very quickly. When the research and development meeting ended, he immediately divided his forces into two groups.
On the one hand, we began to arrange for department doctors to communicate with patients with compensated cirrhosis about the treatment plan for "Ecofovir" and to clarify the risks of medication;
On the other hand, we started to contact Qingshan Pharmaceutical, hoping that Qingshan The pharmaceutical industry can also get involved.
The next day, Zhang Yang received an invitation from the Infectious Diseases Department of the Third People's Hospital.
In the office, Wei Tian is reporting to Zhang Yang.
"Mr. Zhang, this is probably the situation. They are planning to use 'ekofovir' on patients with liver cirrhosis and have invited us to be technical consultants."
"What do you think of the reply? I think we are going to do 'Phase 4 clinical trials', so we can participate."
Phase 4 clinical trials means that after the new drug is put on the market, pharmaceutical companies will continue Examine the efficacy and adverse effects of new drugs under widespread use,
as well as evaluate the risks of use in special populations and improve dosing.
Of course, because the fourth clinical phase is not like the first, second and third clinical phases that determine the drug launch, most pharmaceutical companies in the fourth clinical phase are advancing slowly or stagnantly.
But this is not the focus of Zhang Yang’s concern.
He thought of the "hepatocyte regeneration-promoting activator" obtained in the system.
In fact,
After the overall situation of "Ecofovir" was decided, he slightly modified the relevant pharmaceutical ingredients and activators of this "hepatocyte activator" drug. Give it to Wei Tian.
Wei Tian did not have any doubts.
After Zhang Yang led the R&D team to show amazing abilities in "Acofenprovir", he was completely convinced. In his eyes, Mr. Zhang Yang was a real genius.
It sounds "fantasy" to say this, but people who have actually participated in front-line scientific research know that whether it is national aerospace projects or chip research and development in the commercial field;
or various key projects in major universities, medicine For corporate biopharmaceuticals,
99% of the real decision on whether a project will be successful or not depends on the leader of the project, which is the one or two top geniuses.
And the other 95% of the entire R&D team can be said to be "soy sauce"...
It may not be accurate to say soy sauce. After all, those who can participate in major projects are industry professionals. High-end talents, but compared to the irreplaceability of leaders, there are many people who can be replaced by high-end talents.
For example, although Zhang Yang did a good job at Beifeng Pharmaceutical before, most of the work was completed within the work framework set by the leader. If he can do it, other talents with work experience can also do it.
So,
when Wei Tian heard Zhang Yang say that this "liver cell activator" was accidentally discovered during the development of "Ecofovir",
After discovering that it was an activator that could regenerate liver cells, he immediately mobilized a research and development team to start further research on Zhang Yang's discovery.
This is the role of a leader.
Thinking of this, Zhang Yang thought about the invitation from the Third People's Hospital, thought for a moment, and said:
"Let's do it. I happen to be free today, so you and I can go to the Third People's Hospital to have a look."
(End of this chapter)